Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Publication Details

COVID-19 and the Indo-Pacific: implications for resource-limited emergency departments

Woodruff IG, Mitchell RD, Phillips G, Sharma D, Toito'ona P, Jayasekera K, Wah KS, Cox M, O'Reilly GM

(2020), MED J AUSTRALIA, 213(8), 345-9.e1

DOI: 10.5694/mja2.50750

Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma

Mason R, Dearden HC, Nguyen B, Soon JA, Smith JL, Randhawa M, Mant A, Warburton L, Lo S, Meniawy T, Guminski A, Parente P, Ali S, Haydon A, Long GV, Carlino MS, Millward M, Atkinson VG, Menzies AM

(2020), PIGM CELL MELANOMA R, 33(2), 358-65

DOI: 10.1111/pcmr.12831

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suciu S

(2020), JAMA Oncol, 6(4), 519-27

DOI: 10.1001/jamaoncol.2019.5570

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, Millward M, Begbie S, Brown M, Markman B, Patterson W, Hill A, Horvath L, Nagrial A, Richardson G, Jackson C, Friedlander M, Parente P, Tran B, Wang L, Chen Y, Tang Z, Huang W, Wu J, Zeng D, Luo L, Solomon B

(2020), J Clin Oncol, 38(19), 2140-50

DOI: 10.1200/JCO.19.02654

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy

Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, Mangana J, Atkinson V, Zaman F, Young A, Hoeller C, Hersey P, Dummer R, Khattak MA, Millward M, Patel SP, Haydon A, Johnson DB, Lo S, Blank CU, Sandhu S, Carlino MS, Larkin JMG, Menzies AM, Long GV

(2020), Ann Oncol, 31(8), 1075-82

DOI: 10.1016/j.annonc.2020.04.471

Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises

Bhave P, Haydon A

(2020), Australas J Dermatol, 61(3), 203-9

DOI: 10.1111/ajd.13309

Caution in the age of optimism; a salient lesson in advanced melanoma

Roberts HN, Haydon A

(2020), Ann Transl Med, 8(11), 720

DOI: 10.21037/atm.2020.01.125

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, Chiarion Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Gasal E, Tan M, Long GV, Schadendorf D

(2020), NEW ENGL J MED, 383(12), 1139-48

DOI: 10.1056/NEJMoa2005493

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C

(2020), J Clin Oncol, 38(33), 3925-36

DOI: 10.1200/JCO.20.02110

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma

Atkinson V, Khattak A, Haydon A, Eastgate M, Roy A, Prithviraj P, Mueller C, Brignone C, Triebel F

(2020), J Immunother Cancer, 8(2), e001681

DOI: 10.1136/jitc-2020-001681

Clinimetrics: The Intensive Care Unit Mobility Scale

Tipping CJ, Hodgson CL

(2020), J Physiother, 66(4), 271

DOI: 10.1016/j.jphys.2020.06.001

Physiotherapy management for COVID-19 in the acute hospital setting: clinical practice recommendations

Thomas P, Baldwin C, Bissett B, Boden I, Gosselink R, Granger CL, Hodgson C, Jones AY, Kho ME, Moses R, Ntoumenopoulos G, Parry SM, Patman S, van der Lee L

(2020), J Physiother, 66(2), 73-82

DOI: 10.1016/j.jphys.2020.03.011

Progressive active mobilization with dose control and training load in critically ill patients (PROMOB): Protocol for a randomized controlled trial

Queiroz RS, Saquetto MB, Martinez BP, Cazeta BBR, Hodgson C, Gomes-Neto M

(2020), PLoS One, 15(9), e238352

DOI: 10.1371/journal.pone.0238352

Survival and functional outcome at hospital discharge following in-hospital cardiac arrest (IHCA): A prospective multicentre observational study

Pound G, Jones D, Eastwood GM, Paul E, Hodgson CL; ANZ-CODE Investigators

(2020), Resuscitation, 155, 48-54

DOI: 10.1016/j.resuscitation.2020.07.007

A survey of extracorporeal membrane oxygenation practice in 23 Australian adult intensive care units

Linke NJ, Fulcher BJ, Engeler DM, Anderson S, Bailey MJ, Bernard S, Board JV, Brodie D, Buhr H, Burrell AJC, Cooper DJ, Fan E, Fraser JF, Gattas DJ, Higgins AM, Hopper IK, Huckson S, Litton E, McGuinness SP, Nair P, Orford N, Parke RL, Pellegrino VA, Pilcher DV, Sheldrake J, Reddi BAJ, Stub D, Trapani TV, Udy AA, Hodgson CL; EXCEL Investigators

(2020), Crit Care Resusc, 22(2), 166-70

Clinical Practice Guidelines for Early Mobilization in the ICU: A Systematic Review

Lang JK, Paykel MS, Haines KJ, Hodgson CL

(2020), Crit Care Med, 48(11), e1121-8

DOI: 10.1097/CCM.0000000000004574

Fat embolism syndrome: Experience from an Australian trauma centre

Kirk A, Elliott J, Varma D, Kimmel L

(2020), International Journal of Orthopaedic and Trauma Nursing, 36, 100746

DOI: 10.1016/j.ijotn.2019.100746

High-Flow Nasal Cannula Compared With Conventional Oxygen Therapy or Noninvasive Ventilation Immediately Postextubation: A Systematic Review and Meta-Analysis

Granton D, Chaudhuri D, Wang D, Einav S, Helviz Y, Mauri T, Mancebo J, Frat JP, Jog S, Hernandez G, Maggiore SM, Hodgson CL, Jaber S, Brochard L, Trivedi V, Ricard JD, Goligher EC, Burns KEA, Rochwerg B

(2020), Crit Care Med, 48(11), e1129-e1136

DOI: 10.1097/CCM.0000000000004576

The perceived barriers and facilitators to implementation of ECMO services in acute hospitals

Fulcher BJ, Nicholson AJ, Linke NJ, Berkovic D, Hodgson CL; EXCEL Study Investigators and the International ECMO Network

(2020), INTENS CARE MED, 46(11), 2115-7

DOI: 10.1007/s00134-020-06187-z

Physical activity for cystic fibrosis: perceptions of people with cystic fibrosis, parents and healthcare professionals

Denford S, Cox NS, Mackintosh KA, McNarry MA, O'Halloran P, Holland AE, Tomlinson OW, Barker AR, Williams CA

(2020), ERJ Open Research, 6(3), 00029-2019

DOI: 10.1183/23120541.00294-2019